Pathways' Pick of the Week: A Record Year for Novel Devices

article image
ARTICLE SUMMARY:

CDRH approved a record number of novel devices in 2023. Excerpted from Pathways' Picks January 17: “China on Real-World Studies, IMDRF Heads to DC, Medicare Picks, and EU News.

FDA’s device center authorized 124 devices that it categorizes as “novel” in 2023, “the highest number of novel medical devices on record,” CDRH announced in the January 17 release of its 2023 annual report. The novel device count, which excludes emergency use authorizations, totals original and panel-track PMAs, De Novos, original Humanitarian Device Exemptions, and Breakthrough Device 510(k) clearances. A few other factoids from the annual report:

  • CDRH authorized (PMA, De Novo, and 510(k) 29 Breakthrough Devices in 2023, the most since the program was launched;  
  • 21 device have transitioned from EUAs to traditional marketing authorizations; and
  • All 141 positions funded by MDUFA V for FY 2023 were filed.
Continue reading Pathways’ Picks here.
×



Articles from David Filmore:

Regulatory & Reimbursement

Venture Fund on TAP: Shuren and Former FDA Colleagues Launch New Firm

Former leaders of CDRH want to take the thinking behind the device center's TAP program into the venture capital world. Longtime center director Jeff Shuren is joining former CDRH Chief Scientist Douglas Kelly and others to launch White Oak 66 Capital, seeking to combine medtech investing with a heavy focus on helping firms proactively address reimbursement and other post-FDA commercialization risks.

Read Article